<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717492</url>
  </required_header>
  <id_info>
    <org_study_id>1512M81981-Observational</org_study_id>
    <nct_id>NCT04717492</nct_id>
  </id_info>
  <brief_title>An Observational Study of Beta-Blocker Use in Patients With COPD and Acute MI</brief_title>
  <acronym>BLOCK2</acronym>
  <official_title>An Observational Study of Beta-Blocker Use in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, observational study of patients admitted to the BLOCK COPD&#xD;
      network hospitals with acute AMI and COPD to determine the prevalence of COPD in patients&#xD;
      admitted to the hospital with an acute myocardial infarction (AMI) and to characterize the&#xD;
      phenotypic expression and severity of their underlying lung disease. Patients with will be&#xD;
      identified via the EMR. 571 participants will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1. To determine the prevalence of COPD in patients admitted to the hospital with&#xD;
      an acute myocardial infarction (AMI) and to characterize the phenotypic expression and&#xD;
      severity of their underlying lung disease.&#xD;
&#xD;
      Patients admitted to the hospital and who undergo cardiac catheterization for an AMI will be&#xD;
      identified through the electronic medical record (EMR). Those with a diagnosis of COPD in the&#xD;
      EMR will be offered participation in the study. Baseline characterization will include&#xD;
      demographics, smoking history, prior history of exacerbations in the year before admission,&#xD;
      supplemental oxygen use, respiratory and cardiac medication use, comorbidities including&#xD;
      history of coronary artery disease, heart failure and ejection fraction, and pulmonary&#xD;
      function data as available in the EMR. Results of this Aim will provide data about the&#xD;
      prevalence and clinical characteristics of COPD in the hospitalized population with AMI in&#xD;
      our network. The Aim will also provide an estimate of the number of annual admissions for&#xD;
      patients with COPD and AMI.&#xD;
&#xD;
      Specific Aim 2. To determine the association between beta-blocker use at discharge and&#xD;
      cardiopulmonary outcomes in patients with COPD and AMI.&#xD;
&#xD;
      Patients with AMI and EMR-documented COPD will be followed, prospectively from the time of&#xD;
      discharge using review of the electronic medical record and as local guidance permits, phone&#xD;
      calls at 3 and 6 months. The investigators will determine the associations between&#xD;
      beta-blocker use at discharge and the risk for all-cause mortality, recurrent ischemic&#xD;
      events, and hospitalization for COPD exacerbation adjusting for baseline characteristics and&#xD;
      COPD severity.&#xD;
&#xD;
      Because of the current COVID-19 pandemic and the possibility of limited access to&#xD;
      hospitalized patients, the study consists of three options for enrollment. Option 1 or 2 is&#xD;
      preferable if local guidance permits.&#xD;
&#xD;
      Option 1: A total of 3 visits including 1 in person visit in the hospital and 2 follow up&#xD;
      phone calls with EMR review at 3 and 6 months after discharge. Sites may consider&#xD;
      alternatives to in person consent and data collection including by telephone or video&#xD;
      conference.&#xD;
&#xD;
      Option 2: EMR review at the time of hospital admission followed by post-discharge telephone&#xD;
      consent and 2 follow up phone calls with EMR review at 3 and 6 months.&#xD;
&#xD;
      Option 3: EMR review at the time of hospital admission and follow-up review of the EMR at 3&#xD;
      and 6 months after discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of COPD in patients admitted to the hospital with an acute myocardial infarction (AMI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Results of this Aim will provide data about the prevalence of COPD in the hospitalized population with AMI in our network.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the phenotypic expression and severity of underlying lung disease.</measure>
    <time_frame>Baseline</time_frame>
    <description>Results of this Aim will provide data about the clinical characteristics of COPD in the hospitalized population with AMI in our network.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between beta-blocker use at discharge and cardiopulmonary outcomes in patients with COPD and AMI.</measure>
    <time_frame>6 Months</time_frame>
    <description>Patients with AMI and EMR-documented COPD will be followed, prospectively from the time of discharge using review of the electronic medical record and as local guidance permits, phone calls at 3 and 6 months. The investigators will determine the associations between beta-blocker use at discharge and the risk for cardiopulmonary outcomes.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">571</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Observational</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects hospitalized and who undergo cardiac catheterization with AMI and have&#xD;
        EMR-documented COPD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent (applicable for Option 1 and 2 only)&#xD;
&#xD;
          2. Men and women age 35 or older&#xD;
&#xD;
          3. Admitted to hospital from the Emergency Department or by hospital to hospital transfer&#xD;
             with a primary diagnosis of AMI&#xD;
&#xD;
          4. Undergo cardiac catheterization for AMI&#xD;
&#xD;
          5. EMR-documented COPD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cognitive disorder that in the judgment of the investigator impairs understanding of&#xD;
             the study objectives or assessments (applicable for Option 1 only)&#xD;
&#xD;
          2. Vulnerable populations, including prisoners and pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Dransfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Connett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Lazarus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Dransfield, MD</last_name>
    <phone>205-986-0101</phone>
    <email>mdransfield@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Lindberg, MPH</last_name>
    <phone>612-626-9011</phone>
    <email>slindberg@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Westfall</last_name>
      <phone>205-934-9282</phone>
      <email>ewestfal@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Dransfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco-Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janna Blaauw, CCRP</last_name>
      <phone>559-499-6677</phone>
      <email>jblaauw@fresno.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Vipul Jain, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LA BioMed at Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allison Weber</last_name>
      <phone>310-974-9567</phone>
      <email>aweber@labiomed.org</email>
    </contact>
    <investigator>
      <last_name>William Stringer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Casaburi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Yturralde</last_name>
      <phone>415-502-1852</phone>
      <email>sara.yturralde@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen C. Lazarus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prescott G. Woodruff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical &amp; Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Underwood</last_name>
      <phone>303-398-1518</phone>
      <email>underwoodj@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Barry Make, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Solis</last_name>
      <phone>352-548-6000</phone>
      <phone_ext>4599</phone_ext>
      <email>omerea.solis@va.gov</email>
    </contact>
    <investigator>
      <last_name>Peruvemba Sriram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Mater</last_name>
      <phone>312-926-4533</phone>
      <email>kimberly.mater@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ravi Kalhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Romaine, APRN, NP-C</last_name>
      <phone>504-568-3452</phone>
      <email>cromai@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Lammi, MD, MSCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Reed, MD</last_name>
      <email>rreed@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Reed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tameka Lewis</last_name>
      <email>tchikwe@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>MeiLan Han, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnn Tallman</last_name>
      <phone>612-467-5279</phone>
      <email>tallm002@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Ken Kunisaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HealthPartners Research Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Sasse</last_name>
      <phone>952-967-5169</phone>
      <email>cheryl.l.sasse@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Charlene McEvoy, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura L. Hammel, M.A., CCRP</last_name>
      <email>Hammel.Laura@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Scanlon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Brooklyn Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Puja Chadha</last_name>
      <phone>718-780-5906</phone>
      <email>puc9004@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Jeremy Weingarten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian/Queens</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Ingenito, CCMA, CCRP</last_name>
      <phone>718-670-2414</phone>
      <email>sui9006@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Itzkowitz</last_name>
      <phone>212-746-4377</phone>
      <email>jai2009@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Keith Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alicia Morris</last_name>
      <phone>646-962-2741</phone>
      <email>ajm2017@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Kaner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Kersey</last_name>
      <phone>513-861-3100</phone>
      <phone_ext>4871</phone_ext>
      <email>kimberly.kersey@va.gov</email>
    </contact>
    <investigator>
      <last_name>Ralph Panos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rick Rice, RRT, MEd</last_name>
      <phone>216-444-1150</phone>
      <email>ricer@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Umur Hatipoglu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Rozen</last_name>
      <email>robin.rozen@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Criner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Yost</last_name>
      <phone>412-383-1607</phone>
      <email>ayost@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Sciurba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-4701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Villegas</last_name>
      <phone>801-581-6496</phone>
      <email>martin.villegas@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Richard E Kanner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Gonyaw</last_name>
      <email>Erika.Gonyaw@uvmhealth.org</email>
    </contact>
    <investigator>
      <last_name>David Kaminsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Davis</last_name>
      <phone>509-474-3821</phone>
      <email>lisa.davis2@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Tracy Roundy</last_name>
      <email>tracy.roundy@providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Allison Lambert, MD MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Cardiac</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Beta blockers</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Cardiac Catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

